EMA Panel Gives Thumbs-up to Fenofibrate/Simvastatin ComboEMA Panel Gives Thumbs-up to Fenofibrate/Simvastatin Combo

The drug, known as Cholib, received a "positive opinion" from CHMP for two doses of the fenofibrate/simvastatin combination. A positive opinion is a prerequisite to approval by the European Commission, which has 67 days from the date of the opinion to grant approval. International Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news

Related Links:

Publication date: Available online 21 September 2018Source: Trends in Pharmacological SciencesAuthor(s): Mohammad Mohajeri, Maciej Banach, Stephen L. Atkin, Alexandra E. Butler, Massimiliano Ruscica, Gerald F. Watts, Amirhossein SahebkarCardiovascular disease (CVD) is a major cause of death globally. Addressing cardiovascular risk factors, particularly dyslipidemia, represents the most robust clinical strategy towards reducing the CVD burden. Statins inhibit 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and represent the main therapeutic approach for lowering cholesterol and reducing plaque formation/rupture. The prot...
Source: Trends in Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research
Publication date: October 2018Source: Canadian Journal of Cardiology, Volume 34, Issue 10, Supplement 1Author(s): C. Wen, K. Nerenberg, J. Johnson, R. Sigal, T. Anderson, A. Metcalfe
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
The market of nutritional supplements is expected to expand over 6%/year through 2018 due to growing interest in personal health, aging population, and promising personalized care products. The most used dietary supplements are fish oil, multivitamins, Vitamin D, and coenzyme Q10 (CoQ10) in this order, while probiotics is the fastest growing supplement. In the U.S., over 68% of the population use dietary supplements regularly. On the other hand, in the developed countries, cardiovascular diseases (CVDs) are the main cause of death and morbidity from the 1900s. The effects of most dietary supplements on cardiovascular risk ...
Source: International Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
CONCLUSION: Chronic inflammatory and oxidative and nitrosative stress is associated with the development of a 'leaky gut'. The following evidence-based approaches, which address the leaky gut and blood-brain barrier dysfunction, are suggested as potential therapeutic interventions for neurological and neuropsychiatric disorders: melatonin, statins, probiotics containing Bifidobacteria and Lactobacilli, N-acetylcysteine, and prebiotics containing fructo-oligosaccharides and galacto-oligosaccharides. PMID: 30231628 [PubMed - in process]
Source: The Australian and New Zealand Journal of Psychiatry - Category: Psychiatry Authors: Tags: Aust N Z J Psychiatry Source Type: research
ASA, polypharmacy, statins and obesity treatments are the topics discussed by Dr John Mandrola in this week ’ s podcasttheheart.org on Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Effect of simvastatin on expression of VEGF and TGF-β1 in atherosclerotic animal model of type 2 diabetes mellitus. Exp Ther Med. 2018 Oct;16(4):2889-2894 Authors: Wang H, Li J, Fu X, Liu Y, Xu Q, Sang L Abstract Expression of vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1) in atherosclerosis animal model of type 2 diabetes mellitus treated with simvastatin was investigated. Clean grade mature Sprague Dawley (SD) rats were divided into three groups: Normal control (n=10), model (n=13) and treatment group (n=13); low-dose simvastatin was administered. ...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Authors: Katsiki N, Mikhailidis DP Abstract The past decade has witnessed considerable progress in the field of lipids. New drugs have been "rapidly" developed and some of these drugs have already been evaluated in event-based large trials. This evidence has led to the guidelines recommending new, more aggressive treatment goals for low-density lipoprotein cholesterol (LDL-C) levels. Although LDL-C remains the principal goal for cardiovascular disease (CVD) risk reduction, there has also been considerable interest in other lipid variables, such as high-density lipoprotein cholesterol, triglycerides, and l...
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research
Elevated triglyceride levels may contribute to a greater risk for cardiovascular disease despite statin-controlled LDL cholesterol levels.Journal of Clinical Endocrinology &Metabolism
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Patients with familial hypercholesterolemia (FH) are at increased risk for premature and subsequent cardiovascular disease. Data on long-term major adverse cardiovascular events (MACE) in patients with FH after percutaneous coronary intervention (PCI) in the era of high-intensity statins are scarce.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Source Type: research
Jose A. F. Braga Filho, Afonso G. Abreu, Carlos E. P. Rios, Liana O. Trov ão, Dimitri Luz F. Silva, Dalila N. Cysne, Johnny R. Nascimento, Thiare S. Fortes, Lucilene A. Silva, Rosane N. M. Guerra, Márcia C. G. Maciel, Carlos H. Serezani, Flávia R. F. Nascimento
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Cardiology | Fenofibrate | Grants | Heart | Simvastatin | Statin Therapy | Tricor | Zocor